Seeking Alpha

Sanofi's (SNY) Genzyme announces the publication of results from its studies of Lemtrada in...

Sanofi's (SNY) Genzyme announces the publication of results from its studies of Lemtrada in patients with relapsing-remitting multiple sclerosis, in the November 1 online issue of The Lancet. Results show the drug was significantly more effective at reducing annualized relapse rates than its active competitor Rebif, and more patients on Lemtrada were relapse-free at two years. In addition, accumulation of disability was significantly slowed, and patients experienced actual improvement in disability scores, suggesting a reversal of disability in some patients. Shares +0.7% AH.
Comments (1)
  • Goeleven
    , contributor
    Comments (629) | Send Message
     
    I bought just in time some more sny stocks.
    1 Nov 2012, 07:03 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|